$327 Million is the total value of Samsara BioCapital, LLC's 41 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | RAYZEBIO INC | $40,980,046 | – | 1,845,948 | +100.0% | 12.54% | – | |
| Buy | ACELYRIN INC | $24,220,658 | -48.6% | 2,381,579 | +5.6% | 7.41% | -10.4% | |
| Buy | HILLEVAX INC | $10,750,235 | +4.4% | 799,274 | +33.4% | 3.29% | +82.0% | |
| INZY | New | INOZYME PHARMA INC | $6,562,500 | – | 1,562,500 | +100.0% | 2.01% | – |
| Buy | IO BIOTECH INC | $5,132,421 | +160.3% | 3,640,015 | +261.0% | 1.57% | +354.0% | |
| GOSS | New | GOSSAMER BIO INC | $5,105,287 | – | 6,130,268 | +100.0% | 1.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.